ウイルス性胃腸炎の2030年までの市場予測：タイプ別、診断別、治療別、薬剤別、投薬別、適応症別、投与経路別、流通チャネル別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、世界のウイルス性胃腸炎市場は2023年に471億6,000万米ドルを占め、予測期間中のCAGRは6.6％で成長し、2030年には737億7,000万米ドルに達すると予測されています。

胃腸炎はウイルス性胃腸炎とも呼ばれ、腸や胃に炎症を引き起こす感染性腸疾患です。ロタウイルス、アデノウイルス、ノロウイルスが主な原因ウイルスです。感染力が強いため、通常、汚染された食物や水、あるいは感染者との親密な接触によって感染が広がります。また、下痢、嘔吐、腹部の痙攣、発熱、吐き気などが一般的な症状であり、重症化すると脱水症状を引き起こします。

米国のフィットネス・ウェルネス企業Bodibio社が33カ国、73,076人の成人を対象に行った調査報告によると、調査対象者の40％が機能性胃腸障害（機能性ディスペプシア、過敏性腸症候群、機能性便秘などあらゆるバリエーションを含む）を患っていました。

ウイルス付着の広がり

ロタウイルスやノロウイルスのような胃腸炎を引き起こすウイルスは感染力が非常に強いため、集団感染が拡大する大きな要因となっています。ウイルスの伝播は主に、人から人への接触、エアロゾル化した嘔吐物の粒子、汚染された表面を通して起こる。さらに、特に混雑した環境や対人接触が密接なコミュニティでは、このような感染性の増加が、ウイルス性胃腸炎の迅速かつ広範な発生に一役買っています。

的を絞った抗ウイルス治療の欠如

ノロウイルスを含む多くの原因物質に対する特異的な抗ウイルス薬がないことは、ウイルス性胃腸炎を治療する上で大きな障壁となっています。一般的に抗生物質で治療される細菌感染とは対照的に、ウイルス性胃腸炎の支持療法は主に水分補給と症状の緩和に重点を置いています。さらに、標的抗ウイルス薬がないため、治療介入の選択肢は限られています。

ワクチンの研究開発

胃腸炎ウイルス、特にノロウイルスに対する強力なワクチンの製造に向けた研究開発は、大きなチャンスです。ワクチン開発への新しいアプローチは、宿主の免疫応答とウイルスのゲノミクスへの理解が深まることで可能になります。さらに、ワクチンが成功すれば、予防対策が一変し、胃腸炎アウトブレイクの発生率や強度が低下する可能性があります。

特異的抗ウイルス療法の欠如

大きな脅威のひとつは、多くの胃腸炎ウイルスに特異的な抗ウイルス薬がないことです。ウイルス性胃腸炎は主に支持療法で治療され、治療介入の選択肢は限られています。さらに、重篤な症例の管理は、標的を絞った抗ウイルス治療がないため、より困難になっています。

COVID-19の影響：

ウイルス性胃腸炎の市場はCOVID-19の大流行によって影響を受けています。世界のヘルスケアシステムがパンデミックの制圧に集中したため、ウイルス性胃腸炎の有病率にばらつきが生じた。COVID-19の蔓延を食い止めようと、ロックダウン、社会的距離の取り方、衛生習慣の改善などが行われ、感染する胃腸炎ウイルスの数はいくらか減少しました。さらに、胃腸炎患者の正確な追跡と管理は、パンデミックに対する社会的関心と資源の変化、監視活動の低下、ヘルスケアサービスの中断のため、困難であることが判明しています。

予測期間中、ロタウイルス分野が最大となる見込み

世界的に公衆衛生に広く影響を及ぼしていることから、ロタウイルスセグメントはウイルス性胃腸炎において圧倒的な力を持ち、最大の市場シェアを占めています。さらに、ロタウイルス感染症は、特に幼児における重度の下痢の主な原因であることでよく知られています。また、胃腸炎に関連する罹患率および死亡率の全体的な負担を大幅に増加させる。このウイルスは感染力が強く、さまざまな環境に適応するため、保育施設やヘルスケアへのアクセスが悪い地域など、幅広い環境で頻繁に見られます。

予測期間中、CAGRが最も高くなると予想されるのは外来ケアセンター分野です。

CAGRが最も高い外来ケアセンター分野は、ヘルスケア分野でますます重要性を増しています。これらのセンターは、外来患者サービス、診断、予防医療の提供に特化しているため、ヘルスケア提供の変革に不可欠です。さらに、外来医療の成長を後押ししているのは、患者中心のモデルへのシフトと、手頃な価格で簡単に利用できるヘルスケアオプションへの需要の高まりです。

最大のシェアを占める地域

北米が継続的に最大の市場シェアを占めています。同地域の優位性は、洗練されたヘルスケアインフラ、研究開発への多額の投資、弾力的な規制枠組み、医療支出の増加といった要因が複合的に作用しているためと考えられます。しかし、洗練された医療技術、確固たる地位を確立した製薬産業、充実した医療制度を持つ米国は、特に北米ヘルスケア市場の主要促進要因として際立っています。

CAGRが最も高い地域：

予測期間中、CAGRが最も高くなると予想されるのは欧州地域です。欧州は、確立されたヘルスケア・インフラ、高水準の医学研究と技術革新、広範な医療制度により、世界のヘルスケア市場で常に大きなシェアを占めています。さらに、人口の高齢化、慢性疾患の頻度、利用しやすく質の高いヘルスケアの重視などが、世界のヘルスケア分野における欧州の継続的な台頭と影響力を支えています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレーヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界のウイルス性胃腸炎市場：タイプ別

• ノロウイルス
• ロタウイルス
• アストロウイルス
• 腸内アデノウイルス
• その他のタイプ

第6章 世界のウイルス性胃腸炎市場：診断別

• 身体検査
• 迅速便検査

第7章 世界のウイルス性胃腸炎市場：治療別

• 静脈内輸液
• 運動抑制剤
• 電解質
• 制吐薬
• 下痢止め薬
• その他の治療

第8章 世界のウイルス性胃腸炎市場：薬剤別

• 抗生物質
• 制酸薬
• 下剤
• 化学療法薬
• その他の薬剤

第9章 世界のウイルス性胃腸炎市場：投薬別

• 錠剤
• 注射
• その他の投薬

第10章 世界のウイルス性胃腸炎市場：適応症別

• 水様性下痢
• 嘔吐
• 腹痛とけいれん
• めまい
• 下痢
• 吐き気
• 嘔吐
• 頭痛
• 寒気
• 食欲減少
• 熱
• 関節の硬さ
• 発汗
• 筋肉痛
• 減量
• その他の適応症

第11章 世界のウイルス性胃腸炎市場：投与経路別

• 経口
• 静脈内
• その他

第12章 世界のウイルス性胃腸炎市場：流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第13章 世界のウイルス性胃腸炎市場：エンドユーザー別

• 診断センター
• 外来診療センター
• その他のエンドユーザー

第14章 世界のウイルス性胃腸炎市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第15章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第16章 企業プロファイル

• Bausch Health Companies Inc.
• Abbott
• Cipla Inc.
• Sanofi
• Bayer AG
• Allergan
• Dr. Reddy's Laboratories Ltd.
• Johnson & Johnson Private Ltd.
• Takeda Pharmaceutical Company Ltd.
• Valeant Pharmaceuticals
• Astellas Pharma Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Eli Lilly and Company
• Novartis AG
• Janssen Biotech Inc.
• Mylan N.V.

List of Tables

• Table 1 Global Viral Gastroenteritis Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Viral Gastroenteritis Market Outlook, By Type (2021-2030) ($MN)
• Table 3 Global Viral Gastroenteritis Market Outlook, By Norovirus (2021-2030) ($MN)
• Table 4 Global Viral Gastroenteritis Market Outlook, By Rotavirus (2021-2030) ($MN)
• Table 5 Global Viral Gastroenteritis Market Outlook, By Astrovirus (2021-2030) ($MN)
• Table 6 Global Viral Gastroenteritis Market Outlook, By Enteric Adenovirus (2021-2030) ($MN)
• Table 7 Global Viral Gastroenteritis Market Outlook, By Other Types (2021-2030) ($MN)
• Table 8 Global Viral Gastroenteritis Market Outlook, By Diagnosis (2021-2030) ($MN)
• Table 9 Global Viral Gastroenteritis Market Outlook, By Physical Examination (2021-2030) ($MN)
• Table 10 Global Viral Gastroenteritis Market Outlook, By Rapid Stool Test (2021-2030) ($MN)
• Table 11 Global Viral Gastroenteritis Market Outlook, By Treatment (2021-2030) ($MN)
• Table 12 Global Viral Gastroenteritis Market Outlook, By Intravenous Fluids (2021-2030) ($MN)
• Table 13 Global Viral Gastroenteritis Market Outlook, By Antimotility Agents (2021-2030) ($MN)
• Table 14 Global Viral Gastroenteritis Market Outlook, By Electrolytes (2021-2030) ($MN)
• Table 15 Global Viral Gastroenteritis Market Outlook, By Antiemetic Drugs (2021-2030) ($MN)
• Table 16 Global Viral Gastroenteritis Market Outlook, By Antidiarrheal Drugs (2021-2030) ($MN)
• Table 17 Global Viral Gastroenteritis Market Outlook, By Other Treatments (2021-2030) ($MN)
• Table 18 Global Viral Gastroenteritis Market Outlook, By Drug (2021-2030) ($MN)
• Table 19 Global Viral Gastroenteritis Market Outlook, By Antibiotics (2021-2030) ($MN)
• Table 20 Global Viral Gastroenteritis Market Outlook, By Antacids (2021-2030) ($MN)
• Table 21 Global Viral Gastroenteritis Market Outlook, By Laxatives (2021-2030) ($MN)
• Table 22 Global Viral Gastroenteritis Market Outlook, By Chemotherapy Drugs (2021-2030) ($MN)
• Table 23 Global Viral Gastroenteritis Market Outlook, By Other Drugs (2021-2030) ($MN)
• Table 24 Global Viral Gastroenteritis Market Outlook, By Dosage (2021-2030) ($MN)
• Table 25 Global Viral Gastroenteritis Market Outlook, By Tablet (2021-2030) ($MN)
• Table 26 Global Viral Gastroenteritis Market Outlook, By Injection (2021-2030) ($MN)
• Table 27 Global Viral Gastroenteritis Market Outlook, By Other Dosages (2021-2030) ($MN)
• Table 28 Global Viral Gastroenteritis Market Outlook, By Indication (2021-2030) ($MN)
• Table 29 Global Viral Gastroenteritis Market Outlook, By Watery Diarrhea (2021-2030) ($MN)
• Table 30 Global Viral Gastroenteritis Market Outlook, By Vomiting (2021-2030) ($MN)
• Table 31 Global Viral Gastroenteritis Market Outlook, By Abdominal Pain and Cramps (2021-2030) ($MN)
• Table 32 Global Viral Gastroenteritis Market Outlook, By Dizziness (2021-2030) ($MN)
• Table 33 Global Viral Gastroenteritis Market Outlook, By Diarrhea (2021-2030) ($MN)
• Table 34 Global Viral Gastroenteritis Market Outlook, By Nausea (2021-2030) ($MN)
• Table 35 Global Viral Gastroenteritis Market Outlook, By Vomiting (2021-2030) ($MN)
• Table 36 Global Viral Gastroenteritis Market Outlook, By Headache (2021-2030) ($MN)
• Table 37 Global Viral Gastroenteritis Market Outlook, By Chills (2021-2030) ($MN)
• Table 38 Global Viral Gastroenteritis Market Outlook, By Loss of Appetite (2021-2030) ($MN)
• Table 39 Global Viral Gastroenteritis Market Outlook, By Fever (2021-2030) ($MN)
• Table 40 Global Viral Gastroenteritis Market Outlook, By Joint Stiffness (2021-2030) ($MN)
• Table 41 Global Viral Gastroenteritis Market Outlook, By Sweating (2021-2030) ($MN)
• Table 42 Global Viral Gastroenteritis Market Outlook, By Muscle Pain (2021-2030) ($MN)
• Table 43 Global Viral Gastroenteritis Market Outlook, By Weight Loss (2021-2030) ($MN)
• Table 44 Global Viral Gastroenteritis Market Outlook, By Other Indications (2021-2030) ($MN)
• Table 45 Global Viral Gastroenteritis Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 46 Global Viral Gastroenteritis Market Outlook, By Oral (2021-2030) ($MN)
• Table 47 Global Viral Gastroenteritis Market Outlook, By Intravenous (2021-2030) ($MN)
• Table 48 Global Viral Gastroenteritis Market Outlook, By Others (2021-2030) ($MN)
• Table 49 Global Viral Gastroenteritis Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 50 Global Viral Gastroenteritis Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 51 Global Viral Gastroenteritis Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 52 Global Viral Gastroenteritis Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 53 Global Viral Gastroenteritis Market Outlook, By End User (2021-2030) ($MN)
• Table 54 Global Viral Gastroenteritis Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 55 Global Viral Gastroenteritis Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
• Table 56 Global Viral Gastroenteritis Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

According to Stratistics MRC, the Global Viral Gastroenteritis Market is accounted for $47.16 billion in 2023 and is expected to reach $73.77 billion by 2030 growing at a CAGR of 6.6% during the forecast period. The stomach flu, also referred to as viral gastroenteritis, is an infectious intestinal disease that causes inflammation in the intestines and stomach. The rotavirus, adenovirus, and norovirus are the main viruses that cause it. Being highly contagious, the illness usually spreads through contaminated food, water, or intimate contact with an infected person. Moreover, diarrhea, vomiting, cramps in the abdomen, fever, and nausea are common symptoms; in severe cases, dehydration results.

According to a survey report across 33 countries among 73,076 adults by Bodibio, a US-based fitness and wellness company, 40% of those surveyed had a functional gastrointestinal disorder, including all the variations of functional dyspepsia, irritable bowel syndrome, functional constipation, and others.

Market Dynamics:

Driver:

Spread of viral adherence

The highly contagious nature of viruses that cause gastroenteritis, like rotavirus and norovirus, is a major factor in the spread of outbreaks. Viral transmission occurs mainly through person-to-person contact, aerosolized vomit particles, and contaminated surfaces. Additionally, this increased transmissibility, particularly in crowded environments and communities with close interpersonal contact, plays a role in the quick and widespread occurrence of viral gastroenteritis.

Restraint:

Lack of targeted antiviral treatment

The lack of specific antiviral drugs for many of the causative agents, including norovirus, is a significant barrier to treating viral gastroenteritis. In contrast to bacterial infections, which are typically treated with antibiotics, supportive care for viral gastroenteritis primarily focuses on rehydration and symptom relief. Furthermore, therapeutic intervention options are limited due to the absence of targeted antiviral drugs.

Opportunity:

Development and research on vaccines

Research and development efforts aimed at producing potent vaccines against gastroenteritis viruses, particularly noroviruses, present a substantial opportunity. Novel approaches to the development of vaccines could be made possible by growing comprehension of host immune responses and viral genomics. Moreover, a successful vaccine could transform prophylactic measures and lessen the incidence and intensity of gastroenteritis outbreaks.

Threat:

Absence of particularized antiviral therapy

One major threat is the lack of specific antiviral drugs for many gastroenteritis viruses. Viral gastroenteritis is primarily treated with supportive care, with limited options for therapeutic interventions, unlike bacterial infections, which are frequently treated with targeted antibiotics. Additionally, the management of severe cases is made more difficult by the absence of a targeted antiviral treatment.

COVID-19 Impact:

The market for viral gastroenteritis has been affected by the COVID-19 pandemic. As global healthcare systems have primarily concentrated on controlling the pandemic, there have been variations in the prevalence of viral gastroenteritis cases. In an attempt to stop the spread of COVID-19, lockdowns, social distancing measures, and improved hygiene practices have all somewhat reduced the number of gastroenteritis viruses that are being transmitted. Moreover, accurately tracking and managing gastroenteritis cases has proven difficult, due to changes in public attention and resources towards the pandemic, decreased surveillance efforts, and disruptions in healthcare services.

The Rotavirus segment is expected to be the largest during the forecast period

Due to the widespread influence on public health worldwide, the rotavirus segment is a dominant force in the viral gastroenteritis landscape, possessing the largest market share. Additionally, rotavirus infections are well known for being a major cause of severe diarrhea, particularly in young children. They also significantly increase the overall burden of morbidity and mortality associated with gastroenteritis. Due to the virus's high contagiousness and adaptability to different environments, it is frequently found in a wide range of settings, including childcare facilities and areas with poor access to healthcare.

The Ambulatory Care Centers segment is expected to have the highest CAGR during the forecast period

With the highest CAGR, the ambulatory care center segment is becoming more and more important in the healthcare sector. These centers are essential to the transformation of healthcare delivery because they are dedicated to providing outpatient services, diagnostics, and preventive care. Furthermore, the growth of ambulatory care has been driven by a shift towards patient-centric models and an increasing demand for affordable and easily accessible healthcare options.

Region with largest share:

North America has continuously held the largest market share. The region's prominence is ascribed to a confluence of factors such as sophisticated healthcare infrastructure, significant investments in research and development, a resilient regulatory framework, and elevated healthcare spending. However, with its sophisticated medical technology, firmly established pharmaceutical industry, and extensive healthcare system, the United States in particular stands out as a major driver of the North American healthcare market.

Region with highest CAGR:

During the forecast period, the European region is expected to have the highest CAGR. Europe consistently holds a sizable share of the global healthcare market thanks to its well-established healthcare infrastructure, high standards for medical research and innovation, and extensive healthcare systems. Moreover, the aging population, the frequency of chronic illnesses, and the emphasis on accessible and high-quality healthcare all support Europe's continued rise and clout in the world healthcare arena.

Key players in the market:

Some of the key players in Viral Gastroenteritis market include Bausch Health Companies Inc., Abbott, Cipla Inc., Sanofi, Bayer AG, Allerga, Dr. Reddy's Laboratories Ltd, Johnson & Johnson Private Ltd., Takeda Pharmaceutical Company Ltd., Valeant Pharmaceuticals, Astellas Pharma Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Eli Lilly and Company, Novartis AG, Janssen Biotech Inc. and Mylan N.V.

Key Developments:

In September 2023, Bausch + Lomb Corporation, a subsidiary of Bausch Health Companies Inc., announced it has completed its acquisition of XIIDRA® 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

In April 2023, Cipla has signed a perpetual license agreement with Switzerland-based Novartis Pharma AG to manufacture and market Galvus and Galvus combination brands which are used in the treatment of type 2 diabetes from January 1, 2026.

Types Covered:

• Norovirus
• Rotavirus
• Astrovirus
• Enteric Adenovirus
• Other Types

Diagnosis's Covered:

• Physical Examination
• Rapid Stool Test

Treatments Covered:

• Intravenous Fluids
• Antimotility Agents
• Electrolytes
• Antiemetic Drugs
• Antidiarrheal Drugs
• Other Treatments

Drugs Covered:

• Antibiotics
• Antacids
• Laxatives
• Chemotherapy Drugs
• Other Drugs

Dosages Covered:

• Tablet
• Injection
• Other Dosages

Indications Covered:

• Watery Diarrhea
• Vomiting
• Abdominal Pain and Cramps
• Dizziness
• Diarrhea
• Nausea
• Vomiting
• Headache
• Chills
• Loss of Appetite
• Fever
• Joint Stiffness
• Sweating
• Muscle Pain
• Weight Loss
• Other Indications

Route of Administrations Covered:

• Oral
• Intravenous
• Others

Distribution Channels Covered:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

End Users Covered:

• Diagnostic Centers
• Ambulatory Care Centers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Viral Gastroenteritis Market, By Type

• 5.1 Introduction
• 5.2 Norovirus
• 5.3 Rotavirus
• 5.4 Astrovirus
• 5.5 Enteric Adenovirus
• 5.6 Other Types

6 Global Viral Gastroenteritis Market, By Diagnosis

• 6.1 Introduction
• 6.2 Physical Examination
• 6.3 Rapid Stool Test

7 Global Viral Gastroenteritis Market, By Treatment

• 7.1 Introduction
• 7.2 Intravenous Fluids
• 7.3 Antimotility Agents
• 7.4 Electrolytes
• 7.5 Antiemetic Drugs
• 7.6 Antidiarrheal Drugs
• 7.7 Other Treatments

8 Global Viral Gastroenteritis Market, By Drug

• 8.1 Introduction
• 8.2 Antibiotics
• 8.3 Antacids
• 8.4 Laxatives
• 8.5 Chemotherapy Drugs
• 8.6 Other Drugs

9 Global Viral Gastroenteritis Market, By Dosage

• 9.1 Introduction
• 9.2 Tablet
• 9.3 Injection
• 9.4 Other Dosages

10 Global Viral Gastroenteritis Market, By Indication

• 10.1 Introduction
• 10.2 Watery Diarrhea
• 10.3 Vomiting
• 10.4 Abdominal Pain and Cramps
• 10.5 Dizziness
• 10.6 Diarrhea
• 10.7 Nausea
• 10.8 Vomiting
• 10.9 Headache
• 10.10 Chills
• 10.11 Loss of Appetite
• 10.12 Fever
• 10.13 Joint Stiffness
• 10.14 Sweating
• 10.15 Muscle Pain
• 10.16 Weight Loss
• 10.17 Other Indications

11 Global Viral Gastroenteritis Market, By Route of Administration

• 11.1 Introduction
• 11.2 Oral
• 11.3 Intravenous
• 11.4 Others

12 Global Viral Gastroenteritis Market, By Distribution Channel

• 12.1 Introduction
• 12.2 Hospital Pharmacy
• 12.3 Retail Pharmacy
• 12.4 Online Pharmacy

13 Global Viral Gastroenteritis Market, By End User

• 13.1 Introduction
• 13.2 Diagnostic Centers
• 13.3 Ambulatory Care Centers
• 13.4 Other End Users

14 Global Viral Gastroenteritis Market, By Geography

• 14.1 Introduction
• 14.2 North America
  • 14.2.1 US
  • 14.2.2 Canada
  • 14.2.3 Mexico
• 14.3 Europe
  • 14.3.1 Germany
  • 14.3.2 UK
  • 14.3.3 Italy
  • 14.3.4 France
  • 14.3.5 Spain
  • 14.3.6 Rest of Europe
• 14.4 Asia Pacific
  • 14.4.1 Japan
  • 14.4.2 China
  • 14.4.3 India
  • 14.4.4 Australia
  • 14.4.5 New Zealand
  • 14.4.6 South Korea
  • 14.4.7 Rest of Asia Pacific
• 14.5 South America
  • 14.5.1 Argentina
  • 14.5.2 Brazil
  • 14.5.3 Chile
  • 14.5.4 Rest of South America
• 14.6 Middle East & Africa
  • 14.6.1 Saudi Arabia
  • 14.6.2 UAE
  • 14.6.3 Qatar
  • 14.6.4 South Africa
  • 14.6.5 Rest of Middle East & Africa

15 Key Developments

• 15.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 15.2 Acquisitions & Mergers
• 15.3 New Product Launch
• 15.4 Expansions
• 15.5 Other Key Strategies

16 Company Profiling

• 16.1 Bausch Health Companies Inc.
• 16.2 Abbott
• 16.3 Cipla Inc.
• 16.4 Sanofi
• 16.5 Bayer AG
• 16.6 Allergan
• 16.7 Dr. Reddy's Laboratories Ltd.
• 16.8 Johnson & Johnson Private Ltd.
• 16.9 Takeda Pharmaceutical Company Ltd.
• 16.10 Valeant Pharmaceuticals
• 16.11 Astellas Pharma Inc.
• 16.12 Teva Pharmaceutical Industries Ltd.
• 16.13 Sun Pharmaceutical Industries Ltd.
• 16.14 Aurobindo Pharma
• 16.15 Eli Lilly and Company
• 16.16 Novartis AG
• 16.17 Janssen Biotech Inc.
• 16.18 Mylan N.V.